Elicio Therapeutics Inc.

NASDAQ ELTX
$11.48 0.63 5.81%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 21.25 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
79.78M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
62.35M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
12.95M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
125.10 %

Upcoming events Elicio Therapeutics Inc.

All events
No upcoming events scheduled

Stock chart Elicio Therapeutics Inc.

Stock analysis Elicio Therapeutics Inc.

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-1.56 -1.30
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
-5.50 1.15
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-1.28 -0.75
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.36 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-575.92 -50.00

Price change Elicio Therapeutics Inc. per year

3.96$ 11.80$
Min Max

Summary analysis Elicio Therapeutics Inc.

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Elicio Therapeutics Inc.

Revenue and net income Elicio Therapeutics Inc.

All parameters

About company Elicio Therapeutics Inc.

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node"targeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is also developing ELI-007, a multivalent lymph node"targeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph node"targeted AMP peptide vaccine to target p53 hotspot mutations. The company is headquartered in Boston, Massachusetts.
Address:
451 D Street, Boston, MA, United States, 02210
Company name: Elicio Therapeutics Inc.
Issuer ticker: ELTX
ISIN: US28657F1030
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2021-02-05
Sector: Healthcare
Industry: Biotechnology
Site: https://elicio.com